New York, Feb 6, 2026, 18:29 EST — After-hours
- UnitedHealth shares steadied late Friday, capping a turbulent week for U.S. health insurers.
- A new target cut from Mizuho kept focus on the speed of any earnings rebound.
- Biggest levers: Medicare Advantage reimbursement and how medical costs play out.
UnitedHealth Group Incorporated finished the regular session with a 3.4% gain, closing at $277.57. In late after-hours trading, the stock was holding up, last seen up nearly 3% at $276.65.
U.S. stocks bounced back sharply, lifting the Dow above 50,000 and sending major indexes to their biggest monthly gains in a while.
UnitedHealth hasn’t been trading on a single session’s rally. Instead, the focus has shifted toward a broader rethink of managed-care prospects. Investors are watching for any signs that medical costs might be coming down, and the other question hanging out there: how much money Washington will decide to allocate to insurers for Medicare Advantage, the private Medicare option for seniors.
Mizuho has trimmed its price target for UnitedHealth, now calling for $350 instead of $430, but stuck with its Outperform rating. The firm pointed to a delayed earnings rebound following UnitedHealth’s most recent results.
Just a day before, shares of UnitedHealth and Humana each tumbled over 3% in after-hours trading, dragged lower when Molina Healthcare released a disappointing 2026 forecast. The group-wide selloff followed Molina’s weak outlook.
The pressure stuck around. Molina shares sank over 28% on Friday after the company projected 2026 profit well under Wall Street’s estimates and announced plans to leave Medicare Advantage prescription drug plans in 2027. CEO Joseph Zubretsky described 2026 as a “trough year” for Medicaid margins. Reuters
Centene took a more optimistic stance Friday, projecting its 2026 profit to come in ahead of what Wall Street had been expecting, with executives citing improved cost fundamentals as they look toward that year.
UnitedHealth had already set the tone in late January with guidance that pointed to its first annual revenue drop in decades. The company’s outlook zeroed in on the medical care ratio—how much of its premiums go toward medical claims—and flagged potential changes to benefits and geographic reach. James Harlow at Novare Capital weighed in, saying the Medicare proposal “starts to bring in worries about 2027 earnings growth.” Reuters
Friday’s rebound isn’t putting the central issue to rest: are cost trends slowing down quickly enough to counteract policy pressure? If Medicare Advantage rates stay flat or drop, and risk-adjustment rules tighten — that’s the framework that bumps up payouts for sicker members — insurers have less of a buffer to handle rising medical use without taking a hit on margins.
Now to the policy calendar. CMS outlined its plan for Medicare Advantage and Part D in 2027, projecting a net average payment boost of just 0.09%, pending final approval. Comments are open until Feb. 25, with the final rate set to be announced by April 6.
